Portfolio of Investments
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
PRESS RELEASE Safran Announces the Availability of Its 2021 Interim
PRESS RELEASE Safran announces the availability of its 2021 Interim Financial Report Paris, August 4, 2021 Safran (Euronext Paris: SAF) has filed the French version of its 2021 Interim Financial Report (Rapport Financier Semestriel) with the French financial markets authority (Autorité des marchés financiers – AMF). From August 4 2021, this document (PDF) can be viewed on or downloaded from: Safran’s website, at www.safrangroup.com under the heading “Finance”/sub-heading “Publications”, The French Financial Markets Authority’s website, at www.amf-france.org Agenda Q3 2021 revenue October 29, 2021 Capital Markets Day 2021 December 2, 2021 2021 annual results February 24, 2021 * * * * * Safran is an international high-technology group, operating in the aviation (propulsion, equipment and interiors), defense and space markets. Its core purpose is to contribute to a safer, more sustainable world, where air transport is more environmentally friendly, comfortable and accessible. Safran has a global presence, with 76,000 employees and sales of 16.5 billion euros in 2020, and holds, alone or in partnership, world or regional leadership positions in its core markets. Safran undertakes research and development programs to maintain the environmental priorities of its R&T and Innovation roadmap. Safran is listed on the Euronext Paris stock exchange and is part of the CAC 40 and Euro Stoxx 50 indices. For more information : www.safran-group.com / Follow @Safran on Twitter Press Catherine Malek : [email protected] / T +33 (0)1 40 -
Conte Annual Report 2000 / 2001
Coloplast’s Mission Contents Throughout the world we wish to be perceived as depend- Coloplast in brief 2 able providers of consumable products and services. 5 years’ key figures and ratios 3 Our customers are health care professionals and users. Our primary concern is to improve the quality of life of Board and Group Management 4 individuals suffering from a disabling condition. Management report 5 We respond quickly to market needs to ensure the highest level of customer satisfaction. We strive to offer Financial review 11 preferred product ranges based on innovation, advanced technology and cost-effectiveness. Risk factors 15 Accounting policies 17 All employees must be recognised for their empathy with user needs and dependability in business relations. Profit and loss account 19 It is our ambition to attract and retain the best human Balance sheet 20 resources. Consolidated cash flow statement 22 As individuals and as an organisation we will act respon- Auditors’ report and approvals 23 sibly and be socially and environmentally conscious. Notes 24 We strive to be the best within our businesses, thereby achieving growth and value for the company, the em ploy- ees and shareholders. Stakeholder reporting Annual Report 2000 / 2001 – value creation and knowledge management 32 Customers 33 Employees 38 Society 41 Shareholders 43 Indicators for value drivers and value propositions 48 Artist of the year 50 Group addresses Executives Coloplast Mission Coloplast A/S Coloplast, Conveen, Comfeel, Holtedam 1 Amoena, Sween, Compeed, DK-3050 Humlebæk Assura, Easiflex, EasiCath, Coloplast’s Annual Report for 2000/01 has its own Tel. + 45 49 11 11 11 SpeediCath, Biatain, Contreet, microsite on our corporate website at the address: Fax + 45 49 11 15 55 and Prema are registered trade- E-mail: [email protected] marks of the Coloplast Group. -
2020 Annual Report HIGHLIGHTS SHAREHOLDER MANAGEMENT SUSTAINABILITY CORPORATE COMPENSATION FINANCIAL APPENDIX LETTER COMMENTARY REPORT GOVERNANCE REPORT REPORT 2
2020 Annual Report HIGHLIGHTS SHAREHOLDER MANAGEMENT SUSTAINABILITY CORPORATE COMPENSATION FINANCIAL APPENDIX LETTER COMMENTARY REPORT GOVERNANCE REPORT REPORT 2 CONTENTS #TogetherStrong Highlights 3 #TogetherStrong is a tag-name that covers #TogetherStrong aptly describes how we countless initiatives we took to address progressed through and emerged from this Letter to shareholders 7 pressing needs in the dental community extraordinary year. Management commentary 11 in 2020. Straumann Group in brief 12 Strategy in action 17 #TogetherStrong is forward-looking; it Products, solutions and services 21 It started with a website offering scientific expresses purpose, teamwork, courage, Innovation 26 and practical information to help Markets 29 determination, perseverance, moving Business performance (Group) 35 customers and staff through the corona forward and succeeding in turbulent Business performance (Regions) 38 virus crisis. Soon it became a holistic, Business performance (Financials) 44 surroundings – themes that are captured Share performance 46 omni-channel response including a in the pictures and contents of this report. Risk management 49 massive education platform. Sustainability report 57 The #TogetherStrong concept has Corporate governance 80 extended to thousands of activities Compensation report 107 and millions of communications. It demonstrates how the events of 2020 Financial report 123 fuelled our resourcefulness, innovation Appendix 184 and passion for creating opportunities. Global Reporting Initiative (GRI) 185 GRI content -
DWS (CH) II Small and Mid Caps Switzerland
Marketing Material DWS (CH) II Small and Mid Caps Switzerland Equity Funds - Europe - Regions/Countries August 2021 As at 31/08/2021 Fund Data Performance Investment Policy Performance - Share Class FD (in %) The goal of the sub-fund is primarily to achieve long-term growth in Swiss Francs through investment in a portfolio of stocks from Swiss issuers that are listed in a representative Swiss equities index of small and medium enterprises or the small and mid- cap subindex of a Swiss equities index (“the benchmark”). The investment strategy is based on a transparent and comprehensible investment process, focuses on stock selection. Fund Benchmark (since 09/08/2006): SPI EXTRA Total Return (RI) Past performance is no indication of current or future performance, and the performance data do not take account of the commissions and costs Fund Management's Comment incurred on the issue and redemption of units. For detailed comments on the fund and its corresponding markets please see the annual report. Cumulative performance (in %) - share class FD 1 m 1 y 3 y 5 y s. Inception YTD 3 y avg 5 y avg 2017 2018 2019 2020 CHF 3.0 42.7 36.1 77.7 421.8 29.6 10.8 12.2 29.9 -21.6 29.3 1.8 EUR 2.7 42.0 42.2 80.2 650.5 30.2 12.5 12.5 19.4 -18.6 33.7 2.2 BM IN CHF 2.5 34.9 39.1 90.5 284.2 23.7 11.6 13.8 29.7 -17.2 30.4 8.1 Further Characteristics (3 years) / VAR (1 year) - share class FD Volatility 18.36% Maximum Drawdown -21.26% VAR (99%/10 days) 7.23% Sharpe Ratio -- Information Ratio -0.16 Correlation Coefficient 0.97 Alpha -1.26% Beta 1.05 Tracking Error -
Longer Term Investments Medical Devices
Longer Term Investments Medical devices Chief Investment Office GWM | 11 April 2019 6:53 pm BST Lachlan Towart, Analyst; Stefan R Meyer, Analyst • The aging population and growth of the over-65 age group will create more opportunities for companies selling medical products and devices. • Other drivers of this industry include better penetration in emerging markets due to improved infrastructure, innovative new treatments, increased affordability due to rising per-capita GDP and a growing prevalence of "lifestyle diseases" such as obesity due to urbanization. • We identified five key markets for implantable or wearable devices, including consumer products such as hearing aids, dental implants and corrective lenses. We estimate their total market size at USD 114.8bn with a rate of potential growth in the mid-single digits. • The theme is relatively defensive and should appeal to quality- focused investors. We recommend exposure to it via a diversified portfolio of stocks across our preferred markets and segments. Medical devices can assist in the treatment of many conditions. Some reduce the risk of a treated condition worsening, perhaps as an alternative to drug therapy; others improve users' quality of life or functionality; and still others can solve problems untreatable with drugs. Devices like joint replacements effectively offer permanent long-term solutions (i.e. a cure). Medical devices are primarily used by the over-65 age group, whose growth will outpace the broader population's over the coming decades. Demand is also supported by the rise of "lifestyle diseases" like obesity, itself related to urbanization. The medical device industry has matured, but still represents a substantial opportunity, in our view. -
Safran Aircraft Engines Download
SAFRAN AIRCRAFT ENGINES This is a multi-site certificate, additional site details are listed in the appendix to this certificate 10 ALLEE DU BREVENT - COURCOURONNES 91019 EVRY CEDEX - FRANCE Bureau Veritas Certification certify that the Management System of the above organisation has been audited in accordance with the relevant Aerospace Supplier Quality system Certification Scheme EN 9104-001:2013 and found to be in accordance with the requirements of the management system standard detailed below: Standard EN 9100:2018 AS 9100:D - JISQ 9100:2016 Scope of certification DESIGN, DEVELOPMENT, PRODUCTION, DISTRIBUTION, TEST AND SERVICING OF CIVIL AND MILITARY AIRCRAFT ENGINES - DESIGN, DEVELOPMENT, PRODUCTION, DISTRIBUTION, TEST AND SERVICING SATELLITE AND SPACECRAFT PROPULSION SYSTEMS - ASSOCIATED SERVICES PROVIDED TO CIVIL AND MILITARY CUSTOMERS. Certification structure : Campus Certification Issue date: 15 September 2018 Subject to the continued satisfactory operation of the organization’s Management System, this certificate expires on (Certification Expiry date): 14 September 2021 Original certification date: 15 July 2004 Certificate : 7098050-Rev0 Date: 06 September 2018 File number : FR044707-1 Jacques Matillon – Managing DIrector Bureau Veritas Certification France 60, avenue du Général de Gaulle – Immeuble Le Guillaumet - 92046 Paris La Défense Further clarifications regarding the scope of this certificate the applicability of the management system requirements may be obtained by consulting the organization. To check this certificate validity, please call + 33(0) 1 41 97 00 60. APPENDIX SAFRAN AIRCRAFT ENGINES Standard EN 9100:2018 AS 9100:D - JISQ 9100:2016 Scope of certification Site Address Scope 10 ALLEE DU BREVENT COURCOURONNES SIEGE CENTRAL FUNCTIONS 91019 EVRY CEDEX, France RUE HENRI AUGUSTE INDUSTRIALIZATION AND MANUFACTURING OF PARTS AND EVRY-CORBEIL DESBRUÈRES - BP 81 COMPONENTS FOR AIRCRAFT ENGINES. -
Julius Baer Multicooperation Annual Report 2005 As at June 30, 2005 (Audited)
Julius Baer Multicooperation Annual Report 2005 as at June 30, 2005 (audited) Subscriptions are only valid if made on the basis of the current Prospectus, the latest Annual Report and the latest Semi-Annual Report if published thereafter. The Articles of Association, the valid Prospectus and the Annual and Semi-Annual Reports may be obtained free of charge at the representative in Switzerland and the respective paying agent. Only the German version of the present Annual Report has been reviewed by the independent auditor. Consequently, the independent auditor's report only refers to the German version of the Report; other versions result from a conscientious translation made under the responsibility of the Board. In case of differences between the German version and the translation, the German version shall be the authentic text. AN INVESTMENT FUND DOMICILED IN LUXEMBOURG Representative in Switzerland: Julius Baer Investment Funds Services Ltd., Zurich Paying agent in Switzerland: Bank Julius Bär & Co. AG, Bahnhofstrasse 36, Postfach, CH - 8010 Zurich Paying agent in Germany: Bank Julius Bär (Deutschland) AG, Messe Turm, Friedrich-Ebert-Anlage 49, Postfach 15 01 52, D - 60061 Frankfurt on the Main Paying agent in Austria: Erste Bank der oesterreichischen Sparkassen AG, Graben 21, A - 1010 Vienna Contents Page Organisation and Management 4 Independent Auditor's Report 5 Notes to the Financial Statements 6 Julius Baer Multicooperation (Umbrella Fund) MCOO Julius Baer Multicooperation - Emerging Markets Value Stock Fund HESF Julius Baer Multicooperation -
Air Liquide, Airbus E Il Gruppo ADP Collaborano Per Preparare Gli
COMUNICATO STAMPA CONGIUNTO Parigi, 21 Giugno 2021 Air Liquide, Airbus e Groupe ADP insieme per preparare gli aeroporti di Parigi all’era dell’idrogeno Air Liquide, Airbus e Groupe ADP hanno firmato un protocollo d’intesa per preparare l’arrivo dell'idrogeno negli aeroporti entro il 2035 nell'ambito dello sviluppo di velivoli commerciali alimentati a idrogeno. I partner intendono fare leva sulle rispettive competenze per supportare la decarbonizzazione del trasporto aereo e definire le esigenze concrete e le opportunità che l'idrogeno può apportare al settore aeronautico. Questa partnership riflette l'ambizione comune dei tre gruppi di contribuire allo sviluppo di una filiera francese innovativa e strategica in vista di un'aviazione globale senza emissioni di carbonio. Per prepararsi all'arrivo dei primi aerei di linea a idrogeno entro il 2035, gli aeroporti dovranno essere adattati, in particolare per includere la specificità della fornitura di idrogeno liquido. La partnership annunciata oggi si concentra sulla realizzazione di studi di fattibilità finalizzati allo sviluppo di queste infrastrutture. Come primo step, verrà avviato uno studio che coinvolgerà un panel rappresentativo di circa 30 aeroporti in tutto il mondo per valutare le potenziali configurazioni per la produzione, fornitura e distribuzione di idrogeno liquido. Verranno poi elaborati scenari dettagliati e i piani per i due principali aeroporti parigini: Paris-Charles de Gaulle e Paris-Orly. Questi scenari saranno essenziali nella definizione dell'infrastruttura richiesta, inclusi il dimensionamento e la posizione, e per identificare e integrare i vincoli relativi sia agli standard di sicurezza industriale che alle norme previste per l’aeronautica. La partnership riunisce competenze complementari con l'ambizione di supportare, a partire da oggi, la trasformazione degli aeroporti e aprire la strada a una nuova era di viaggi aerei sostenibili. -
Novo Nordisk Annual Report 2012
novo nordisk annual report 2012 Diabetes – an emergency in slow motion Strategy Sustainable growth is all about – can it be done? choice Insulin in Novo Nordisk’s performance in 2012 is a result of important decisions made in recent years a tablet – but there is more to the story – why is it so difficult? Contents Accomplishments and results 2012 1 Letter from the Chairman 2 Letter from the CEO 4 Performance highlights 6 2012 performance and 2013 outlook Our business 15 Strategy is all about choice 20 Diabetes – an emergency Diabetes – an emergency in slow motion 20 in slow motion 22 The protein powerhouse 24 Insulin treatment is a balancing act 26 Insulin in a tablet – why is it so difficult? 28 Simple injections 29 Prevent bleedings 30 Pipeline overview 32 Many markets – one model 38 Sustainable growth – can it be done? 41 With every big opportunity comes a risk Governance, leadership and shares 44 Shares and capital structure The protein 46 Corporate governance 22 powerhouse 49 Remuneration 52 Board of Directors 54 Executive Management Financial, social and environmental statements 55 Consolidated financial, social and environmental statements 104 Financial statements of the parent company 109 Management’s statement and Auditor’s reports Additional information 112 More information Simple 28 injections 113 Product overview The Management review, as defined by the Danish Financial Statements Act (FSA), is found on pp 1–54 and 94. This Annual Report is published in both a Danish and an English language version. In the event of any discrepancies, the Danish version shall prevail. 1 Chairman of the Board of Directors Sten Scheibye at the Annual General Meeting in March 2012. -
View Annual Report
GROWTH THROUGH INNOVATION Halma plc Annual Report and Accounts 2012 Overview 01 Investment Proposition 02 Group at a Glance 04 Strategy and Business Model 06 Innovation in Healthcare and Analysis 08 Innovation in Infrastructure Sensors 10 Innovation in Industrial Safety Business review 12 Chairman’s Statement 14 Performance against Strategy 20 Strategic Review 25 Strategy in Action 30 Sector Reviews 30 Health and Analysis 38 Infrastructure Sensors 46 Industrial Safety 54 Financial Review 59 Risk Management and Internal Control 61 Principal Risks and Uncertainties 64 Corporate Responsibility Governance 68 Board of Directors and Executive Board 71 Chairman’s Introduction to Governance 72 Corporate Governance 76 Audit Committee Report 78 Nomination Committee Report 79 Remuneration Committee Report 80 Remuneration Report 87 Other Statutory Information 90 Directors’ Responsibilities Financial statements 91 Independent Auditor’s Report – Group 92 Consolidated Income Statement 92 Consolidated Statement of Comprehensive Income and Expenditure 93 Consolidated Balance Sheet 94 Consolidated Statement of Changes in Equity 95 Consolidated Cash Flow Statement 96 Accounting Policies 102 Notes to the Accounts 135 Independent Auditor’s Report – Company 136 Company Balance Sheet 137 Notes to the Company Accounts 142 Summary 2003 to 2012 144 Halma Directory 148 Shareholder Information and Advisers Overview Business review Governance Financial statements INVESTMENT PROS PO ITION Halma has an impressive record of creating sustained shareholder value through the economic cycle. We have consistently delivered record profits, high returns, strong cash flows, low levels of balance sheet gearing and have a 30+ year track record of growing dividend payments by 5% or more every year. Our ability to achieve record profits through the recent periods of economic turbulence is derived from our strategy of having a group of businesses building strong competitive advantage in specialised safety, health and environmental technology markets with resilient growth drivers. -
FACTSHEET - AS of 29-Sep-2021 Solactive Switzerland 40 Equal Weight Index TR
FACTSHEET - AS OF 29-Sep-2021 Solactive Switzerland 40 Equal Weight Index TR HISTORICAL PERFORMANCE 6,000 5,000 4,000 3,000 2,000 1,000 Jan-2000 Jan-2005 Jan-2010 Jan-2015 Jan-2020 Solactive Switzerland 40 Equal Weight Index TR CHARACTERISTICS ISIN / WKN DE000SLA98V4 / SLA98V Base Value / Base Date 1000 Points / 03.03.1999 Bloomberg / Reuters SOCH40ET Index / .SOCH40ET Last Price 5520.10 Index Calculator Solactive AG Dividends Included Index Type Total Return Calculation 09:00am to 10:30pm (CET), every 60 seconds Index Currency CHF History Available daily back to 03.03.1999 Index Members 40 FACTSHEET - AS OF 29-Sep-2021 Solactive Switzerland 40 Equal Weight Index TR STATISTICS 30D 90D 180D 360D YTD Since Inception Performance -6.87% -1.29% 6.88% 26.84% 16.30% 452.01% Performance (p.a.) - - - - - 7.86% Volatility (p.a.) 14.33% 11.91% 11.14% 12.42% 11.49% 18.86% High 5927.07 5927.07 5927.07 5927.07 5927.07 5927.07 Low 5498.67 5498.67 5111.72 4101.40 4734.43 549.01 Sharpe Ratio -4.04 -0.43 1.30 2.20 1.96 0.42 Max. Drawdown -7.23% -7.23% -7.23% -8.17% -7.23% -68.82% VaR 95 \ 99 -22.5% \ -33.9% -29.8% \ -57.3% CVaR 95 \ 99 -29.9% \ -44.8% -47.2% \ -78.4% COMPOSITION BY CURRENCIES COMPOSITION BY COUNTRIES CH 97.6% CHF 100.0% AT 2.4% TOP COMPONENTS AS OF 29-Sep-2021 Company Ticker Country Currency Index Weight (%) DUFRY AG DUFN SE Equity CH CHF 2.80% SWISSCOM AG SCMN SE Equity CH CHF 2.69% ALCON INC ALC SE Equity CH CHF 2.67% SONOVA HOLDING AG SOON SE Equity CH CHF 2.64% UBS GROUP AG UBSG SE Equity CH CHF 2.63% JULIUS BAER GRUPPE AG BAER SE Equity CH CHF 2.61% KUEHNE & NAGEL INTERNATIONAL AG KNIN SE Equity CH CHF 2.60% NESTLE SA NESN SE Equity CH CHF 2.60% SWISS LIFE HOLDING AG SLHN SE Equity CH CHF 2.60% CHOCOLADEFABRIKEN LINDT & SPRUENGLI AG LISP SE Equity CH CHF 2.60% FACTSHEET - AS OF 29-Sep-2021 Solactive Switzerland 40 Equal Weight Index TR DISCLAIMER © Solactive AG, 2021. -
VONTOBEL FOREIGN OPPORTUNITIES FUND SCHEDULE of INVESTMENTS (Unaudited) DECEMBER 31, 2020
VONTOBEL FOREIGN OPPORTUNITIES FUND SCHEDULE OF INVESTMENTS (Unaudited) DECEMBER 31, 2020 ($ reported in thousands) Shares Value Shares Value COMMON STOCKS—99.0% Information Technology—continued Keyence Corp. (Japan) 47,705 $ 26,797 Communication Services—5.0% Mastercard, Inc. Class A (United States) 95,484 34,082 Cellnex Telecom SA 144A (Spain)(1) 175,403 $ 10,525 (2) Obic Co. Ltd. (Japan) 110,682 22,221 CTS Eventim AG & Co. KGaA (Germany) 453,514 30,140 Tata Consultancy Services Ltd. (India) 699,816 27,418 Tencent Holdings Ltd. (China) 211,318 15,374 Topicus.com, Inc. (Canada) 55,270 209 56,039 194,876 Consumer Discretionary—14.1% Materials—4.4% adidas AG (Germany)(2) 55,581 20,228 (2) Air Liquide SA (France) 131,929 21,637 Alibaba Group Holding Ltd. (China) 577,713 17,333 Asian Paints Ltd. (India) 716,026 27,091 Alibaba Group Holding Ltd. Sponsored ADR (China)(2) 71,937 16,742 Ferrari NV (Italy) 132,190 30,465 48,728 Flutter Entertainment plc (Ireland)(2) 188,778 38,491 LVMH Moet Hennessy Louis Vuitton SE (France) 55,405 34,580 TOTAL COMMON STOCKS (Identified Cost $725,173) 1,104,557 157,839 TOTAL LONG-TERM INVESTMENTS—99.0% Consumer Staples—18.2% (Identified Cost $725,173) 1,104,557 Alimentation Couche-Tard, Inc. Class B (Canada) 1,014,470 34,573 Asahi Group Holdings Ltd. (Japan)(3) 840,866 34,561 SHORT-TERM INVESTMENT—0.7% Diageo plc (United Kingdom) 966,387 38,034 Mondelez International, Inc. Class A (United States) 460,250 26,911 SECURITIES LENDING COLLATERAL—0.7% Nestle S.A.